Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2

Status

Completed 14Unknown 5Recruiting 5Active not recruiting 5Not yet recruiting 3Terminated 2Withdrawn 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Thoracic 5

Conditions

Breast Neoplasms 1871Neoplasms 1257Colorectal Neoplasms 1057Carcinoma, Non-Small-Cell Lung 1012Stomach Neoplasms 802Carcinoma, Hepatocellular 785Lung Neoplasms 769Prostatic Neoplasms 697Pancreatic Neoplasms 577Rectal Neoplasms 449Ovarian Neoplasms 406Colonic Neoplasms 405Neoplasm Metastasis 403Uterine Cervical Neoplasms 400Recurrence 382Leukemia, Myeloid, Acute 372Esophageal Neoplasms 363Multiple Myeloma 339Lymphoma 335Head and Neck Neoplasms 330Melanoma 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 292Brain Neoplasms 264Urinary Bladder Neoplasms 256Liver Neoplasms 225Nasopharyngeal Carcinoma 223Leukemia 218Lymphoma, Large B-Cell, Diffuse 216Polycystic Ovary Syndrome 210Squamous Cell Carcinoma of Head and Neck 205

Interventions

osimertinib 1abivertinib 1Radiosurgery 1Gefitinib 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Advanced Non-small Cell Lung Cancer × Clear all
NCT03334864 2023-09-11

Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)

Peking Union Medical College Hospital

Unknown
5,000 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT05489731 2023-06-15

VIC-1911

Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.

Phase 1 Unknown
72 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT04990063 2021-08-04

Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC)

Tang-Du Hospital

Phase 1 Unknown
20 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT03856697 2019-02-27

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 3 Unknown
406 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT03727867 2019-01-30

Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer

Taizhou Hospital

Phase 3 Unknown
300 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡